Neuren Pharmaceuticals Limited (ASX:NEU) Insider Joseph(Joe) Basile Acquires 6,406 Shares

Neuren Pharmaceuticals Limited (ASX:NEU) insider Joseph(Joe) Basile bought 6,406 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were purchased at an average cost of A$15.73 ($10.63) per share, with a total value of A$100,766.38 ($68,085.39).

Joseph(Joe) Basile also recently made the following trade(s):

• On Tuesday, June 11th, Joseph(Joe) Basile bought 5,000 shares of Neuren Pharmaceuticals stock. The shares were purchased at an average cost of A$19.49 ($13.17) per share, with a total value of A$97,450.00 ($65,844.59).

Neuren Pharmaceuticals Stock Performance

Neuren Pharmaceuticals Company Profile

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.